Emilio A. Emini - Wayne PA Rima Youil - North Wales PA Andrew J. Bett - Landsdale PA Ling Chen - Blue Bell PA David C. Kaslow - Bryn Mawr PA John W. Shiver - Doylestown PA Timothy J. Toner - Marlton NJ Danilo R. Casimiro - Harleysville PA
First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa sexual stage surface protein of , Pfs25, or the Pfs25 protein purified from host cells infected with the above-described recombinant virus. Mice inoculated with the recombinant virus developed antibodies with transmission blocking activity. The present invention also relates to recombinant viruses used in the vaccines of the present invention, host cells infected with the recombinant viruses of the present invention and methods of preventing or treating malarial infections using the vaccines of the present invention.
David C. Kaslow - Rancho Santa Fe CA, US Takafumi Tsuboi - Shigenobu-cho, JP Motomi Torii - Tobe-cho, JP
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A01N 43/04 A61K 31/70 C07H 21/02 C07H 21/04
US Classification:
514 44, 536 231, 536 237
Abstract:
The present invention relates to novel methods and compositions for blocking transmission of which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
David C. Kaslow - Wayne PA, US Takafumi Tsuboi - Ehime, JP Motomi Torii - Ehime, JP
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/00 A61K 39/015
US Classification:
4241851, 4242721
Abstract:
The present invention relates novel methods and compositions for blocking transmission of which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
Emilio A. Emini - Wayne PA, US David C. Kaslow - Rancho Santa Fe CA, US Andrew J. Bett - Lansdale PA, US John W. Shiver - Chalfont PA, US Alfredo Nicosia - Rome, IT Armin Lahm - Rome, IT Alessandra Luzzago - Rome, IT Riccardo Cortese - Rome, IT Stefano Colloca - Rome, IT
Assignee:
Merck & Co., Inc. - Rahway NJ Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A. - Rome
International Classification:
C07H 21/04 C12N 7/00
US Classification:
536 231, 536 234, 4242181
Abstract:
The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
Emilio A. Emini - Wayne PA, US David C. Kaslow - Rancho Santa Fe CA, US Andrew J. Bett - Lansdale PA, US John W. Shiver - Chalfont PA, US Alfredo Nicosia - Rome, IT Armin Lahm - Rome, IT Alessandra Luzzago - Rome, IT Riccardo Cortese - Rome, IT Stefano Colloca - Rome, IT
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C12N 7/00 C07H 21/04
US Classification:
4242181, 4241891, 536 231, 536 234
Abstract:
The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
David C. Kaslow - Rancho Santa Fe CA, US Andrew J. Bett - Lansdale PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C12N 15/63 C07H 21/04 A61K 48/00
US Classification:
4353201, 536 231, 514 44, 4352523
Abstract:
The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized Hiv1-Gag, Pol.nef And Modifications
Emilio Emini - Wayne PA, US Rima Youil - North Wales PA, US Andrew Bett - Lansdale PA, US Ling Chen - Blue Bell PA, US David Kaslow - Rancho Santa Fe CA, US John Shiver - Chalfont PA, US Timothy Toner - Marlton NJ, US Danilo Casimiro - Harleysville PA, US
First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
David Kaslow 1960 graduate of University High School in Bloomington, IN is on Classmates.com. See pictures, plan your class reunion and get caught up with David and other high ...
The treatment was developed with the US-based non-profit PATH Malaria Vaccine Initiative. David Kaslow, vice president, product development at PATH, said the limited efficacy of the vaccine must be put in context. There has been great progress with bed nets and other technical measures, "yet there i
Date: Oct 08, 2013
Category: Health
Source: Google
First Effective Malaria Vaccine May Be Near, Experts Say
Dr. David Kaslow, vice president of product development at PATH, commented on the importance of the results. "Given the huge disease burden of malaria among African children, we cannot ignore what these latest results tell us about the potential for RTS,S to have a measurable and significant impact
Date: Oct 08, 2013
Category: Health
Source: Google
GlaxoSmithKline aims to market first malaria vaccine next year
Despite these drawbacks, David Kaslow, vice president of product development at PATH, said RTS,S would serve as a useful additional tool alongside other malaria control measures such as mosquito nets, insecticides and anti-malaria drugs.
Date: Oct 07, 2013
Category: Health
Source: Google
Study shows modest benefits for malaria vaccine in infants
David Kaslow, MD, director of the PATH Malaria Vaccine Initiative, said in the press release that determining what role the vaccine might play in Africa will depend on analysis of additional data. "Success in developing malaria vaccines depends on many factors: at the top of the list are
If you broadly implement this across sub-Saharan Africa, it is going to prevent millions of cases and save thousands of lives, said David Kaslow, director of the malaria vaccine initiative at the Program for Appropriate Technology in Health (PATH), a nonprofit group in Seattle that is helping run
Date: Nov 09, 2012
Category: Health
Source: Google
Malaria Vaccine Results: Disappointing But Not The End Of The Story
"Malaria is so prevalent in these African kids," Dr. David Kaslow of the MVI told Shots, "that even a modest protection translates into large public health impact, just given the sheer numbers. So (the vaccine) will reduce disease and it will save lives."